Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smarter heart pacing could cut hospital stays for heart failure patients

NCT ID NCT07684547

Disease control Sponsor: University of Pecs Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests a newer, more natural pacing method for people with heart failure and electrical problems in the heart. The approach uses the heart's own conduction system to improve coordination between chambers. Researchers will track patients for two years to see if this method reduces deaths and hospitalizations compared to standard pacing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cardiac resynchronization therapy using conduction system pacing (left bundle branch area pacing with or without LV lead optimization)
What this could lead to
If successful, this pacing approach could offer a more effective way to synchronize heart contractions, potentially reducing deaths and hospital stays for heart failure patients.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by other factors. The new pacing method may not prove superior to standard therapy in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients with heart failure with reduced ejection fraction (HFrEF) who are treated at the University of Pécs Clinical Centre Heart Institute and meet contemporary guideline indications for cardiac resynchronization therapy (CRT). Eligible participants have symptomatic heart failure despite guideline-directed medical therapy, left ventricular systolic dysfunction, and evidence of electrical dyssynchrony manifested by left bundle branch block (LBBB) or intraventricular conduction delay (IVCD). The prospective cohort includes patients undergoing conduction system pacing-based CRT as part of routine clinical care, while the historical control cohort includes patients previously treated with conventional biventricular CRT at the same institution. The study population represents a real-world heart failure population routinely referred for CRT implantation in tertiary cardiovascular care.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Symptomatic heart failure despite guideline-directed medical therapy. * Left ventricular ejection fraction (LVEF) ≤40%. * Indication for cardiac resynchronization therapy according to contemporary ESC guideline recommendations. * QRS duration ≥150 ms with either: Left bundle branch block (LBBB), or Intraventricular conduction delay (IVCD). * Planned implantation of a CRT system * Ability to provide written informed consent * Expected survival greater than 24 months. Exclusion Criteria: * Age \<18 years and Age 100 \< years * Pregnancy or breastfeeding. * Inability or unwillingness to provide informed consent. * Life expectancy \<12 months due to non-cardiac comorbidities. * Active systemic infection or infection involving a cardiac implantable electronic device. * Reversible causes of heart failure expected to improve without CRT. * Participation in another interventional clinical trial that may affect study outcomes. * Inability to comply with follow-up requirements. * Missing essential baseline or follow-up data (retrospective cohort). * Any condition that, in the opinion of the investigators, would make participation inappropriate or interfere with study assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure - nyha ii - iv are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure progressive familial heart block, type 1A systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure - nyha ii - iv Intraventricular conduction delay Left bundle branch area pacing Left bundle-branch block Resynchronization therapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Heart Institute , University of Pécs

    Pécs, Baranya, 7621, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.